Department of Orthopedic Surgery, China-Japan Union Hospital, Jilin University, Changchun, Jilin, People's Republic of China.
Department of Orthodontics, Hospital of Stomatology, Jilin University, No. 1500 Qinghua Street, Changchun, 130021, Jilin, People's Republic of China.
Sci Rep. 2023 Jun 5;13(1):9118. doi: 10.1038/s41598-023-35745-w.
Immunogenic cell death (ICD) is a form of cell death that stimulates the immune system to produce an immune response by releasing tumour-associated antigens and tumour-specific antigens and is considered to play an important role in tumour immunotherapy. In the present study, we identified two ICD-related subtypes in osteosarcoma (OS) by consensus clustering. The ICD-low subtype was associated with favourable clinical outcomes, abundant immune cell infiltration, and high activity of immune response signalling. We also established and validated an ICD-related prognostic model, which could not only be used to predict the overall survival of OS patients but was also found to be closely related to the tumour immune microenvironment of OS patients. Overall, we established a new classification system for OS based on ICD-related genes, which can be used to predict the prognosis of OS patients and to select appropriate immunotherapy drugs.
免疫原性细胞死亡（ICD）是一种细胞死亡形式，通过释放肿瘤相关抗原和肿瘤特异性抗原来刺激免疫系统产生免疫反应，被认为在肿瘤免疫治疗中发挥重要作用。在本研究中，我们通过共识聚类鉴定出两种骨肉瘤（OS）相关的 ICD 亚型。ICD-低亚型与良好的临床结局相关，具有丰富的免疫细胞浸润和高免疫反应信号活性。我们还建立并验证了一个与 ICD 相关的预后模型，该模型不仅可用于预测 OS 患者的总生存率，而且还与 OS 患者的肿瘤免疫微环境密切相关。总之，我们基于与 ICD 相关的基因建立了一种新的骨肉瘤分类系统，可用于预测 OS 患者的预后，并选择合适的免疫治疗药物。
